Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinjikang Granules is a Traditional Chinese Medicine (TCM) manufactured by Shanghai Pharmaceuticals Group Qingdao Growful Pharmaceutical. It is primarily indicated for the treatment of viral myocarditis, particularly cases characterized by Qi and Yin deficiency. The formulation is designed to tonify Qi, nourish Yin, and activate blood circulation to resolve stasis. Clinical applications focus on protecting the myocardium from inflammatory damage, improving cardiac function, and alleviating symptoms such as palpitations, chest tightness, and shortness of breath. As a multi-herb granule formulation, it is typically administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xinjikang granules.